Advertisement

International Journal of Clinical Pharmacy

, Volume 34, Issue 2, pp 269–271 | Cite as

Unusual high dose of tacrolimus in liver transplant patient, a case report

  • Alessio ProvenzaniEmail author
  • Monica Notarbartolo
  • Manuela Labbozzetta
  • Paola Poma
  • Adele D’Antoni
  • Piera Polidori
  • Giovanni Vizzini
  • Natale D’Alessandro
Case Report

Abstract

Case We describe the case of a liver transplant patient who had great difficulty in reaching the desired trough blood levels despite the use of high dose tacrolimus. The patient was homozygous for the CYP3A5*3 allele. However, the respective donor carried the wild-type CYP3A5*1/*1 genotype. Regarding ABCB1 SNPs at exon 21 and 26, the patient showed the 2677GT and 3435CC genotypes. For the corresponding donor we observed the 2677GG and 3435CC wild-type genotypes. One, two and three weeks after transplantation the patient received daily 0.219, 0.287 and 0.273 mg/kg of tacrolimus, respectively. However, the corresponding tacrolimus trough blood levels were of 4.6, 5.6 and 6.1 ng/mL. The tacrolimus target level of 10.4 ng/mL was finally reached after 1 month of therapy. During the entire period of observation the kidney showed no sign of damage. No other signs of toxicity were reported except for the occurrence of an isolated systolic hypertension. Conclusions CYP3A5 genotyping may represent a useful tool to better evaluate the appropriate initial dose of tacrolimus for patients carrying a liver with the CYP3A5*1/*1 genotype.

Keywords

ABCB1 CYP3A5 Liver transplant Pharmacogenomics Single nucleotide polymorphisms Tacrolimus Trough blood levels 

Notes

Acknowledgments

None.

Funding

This study was supported by Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT) and by University of Palermo.

Conflicts of interests

None to declare.

References

  1. 1.
    Macphee I, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics. Polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation. 2002;74:1486–9.PubMedCrossRefGoogle Scholar
  2. 2.
    van Schaik RHN, Van der Heiden IP, Van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch caucasians. Clin Chem. 2002;48:1668–71.PubMedGoogle Scholar
  3. 3.
    Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther. 2004;42:701–18.PubMedGoogle Scholar
  4. 4.
    Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among Europeans Americans and Africans Americans. Clin Pharmacol Ther. 2001;70:189–99.PubMedCrossRefGoogle Scholar
  6. 6.
    Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D’Alessandro N. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med. 2011;28:1093–102.PubMedGoogle Scholar
  7. 7.
    Bekersky I, Dressler D, Mekki QA. Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg. Clin Ther. 1999;21:2058–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Wei-Lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirements in relation to donor and recipients ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl. 2006;12:775–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Zhang Y, Benet LZ. The gut as a barrier to drug absorption. Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159–68.PubMedCrossRefGoogle Scholar
  10. 10.
    Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther. 2007;82(6):711–25.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Alessio Provenzani
    • 1
    Email author
  • Monica Notarbartolo
    • 2
  • Manuela Labbozzetta
    • 2
  • Paola Poma
    • 2
  • Adele D’Antoni
    • 3
  • Piera Polidori
    • 1
  • Giovanni Vizzini
    • 3
  • Natale D’Alessandro
    • 2
  1. 1.Department of Clinical PharmacyMediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT)PalermoItaly
  2. 2.Department of Health Promotion Sciences “G. D’Alessandro” – Section of Pharmacology “P. Benigno”University of PalermoPalermoItaly
  3. 3.Department of MedicineMediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT)PalermoItaly

Personalised recommendations